Company News: AstraZeneca

Share this article:
AstraZeneca announced plans to cut 8,000 jobs -- around 12% of its global workforce -- by 2014 as part of a cost-cutting exercise. The firm, which has already eliminated 12,600 jobs in recent years, will lose US market exclusivity on Arimidex and Pulmicort Respules this year and has projected a revenue decline in the mid-single digits for the year. The company will also restructure its R&D function to focus on fewer disease area targets and close some R&D sites.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.